

Summary of Curriculum Vitae

As of 10th June 2021

Surname	Takahari
Given name	Daisuke
Degree	M.D., Japan, 1998 No.392807 Ph.D., Sapporo Medical University, Japan, 2007
Sex	Male
Born on	September 25, 1973, Otaru, Hokkaido, Japan
Present post	Vice Director, Department of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Contact information

Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research
3-8-31 Ariake, Koto-ku, Tokyo 135-8550, JAPAN
Tel. +81 3 3520 0111, Fax +81 3 3570 0343
E-mail: daisuke.takahari@jfcr.or.jp

Education and professional career

- Graduated from Faculty of Medicine, Sapporo Medical University in 1998
- Internal Medicine Division, at Sapporo Medical University Hospital in 1998-1999
- Gastroenterology Division at Date Red Cross Hospital in 1999-2001
- Internal Medicine Division, at Sapporo Medical University Hospital in 2001-2002
- Gastroenterology Division at Hakodate national Hospital in 2002-2003
- Internal Medicine Division, at Sapporo Medical University Hospital in 2003
- Internal Medicine Division at Tonan Hospital in 2003-2006
- Resident, National Cancer Center Hospital in 2006-2008
- Physician-in-Chief, Clinical Oncology Department, Aichi Cancer Center Hospital in 2008-2014
- Physician-in-Chief, Department of Gastroenterology, The Cancer Institute Hospital of JFCR in 2014-2021
- Vice Director, Department of Gastroenterology, The Cancer Institute Hospital of JFCR in 2021-now

Research interest

Chemotherapy and immunotherapy of gastrointestinal malignancies

Academic membership

Member of American Society of Clinical Oncology
Member of European Society of Medical Oncology

International Gastric Cancer Association
Japanese Society of Internal Medicine
The Japanese Society of Gastroenterology
Japan Gastroenterological Endoscopy Society
Japanese Society of Medical Oncology
Japanese Society of Clinical Oncology
Japan Cancer Association
Japanese Gastric Cancer Association

Main Publications (First author/corresponding author)

1. Takahari D, Shinozaki E, Wakatsuki T, Ooki A, Ozaka M, Suzuki T, Nakayama I, Osumi H, Kamiimabepu D, Sato T, Ogura M, Suenaga M, Chin K, Yamaguchi K. Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research. *Int J Clin Oncol.* 2021 Feb;26(2):335-344.
2. Takahari D, Chin K, Yamaguchi K. Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy? *Future Oncol.* 2020;16(24):1797-1799.
3. Nakayama I, Takahari D, Wakatsuki T, Osumi H, Chin K, Ogura M, Sato T, Suzuki T, Kamiimabepu D, Ooki A, Suenaga M, Shinozaki E, Yamaguchi K. Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting. *ESMO Open.* 2020;5(2):e000595.
4. Ota Y, Takahari D, Suzuki T, Osumi H, Nakayama I, Oki A, Wakatsuki T, Ichimura T, Ogura M, Shinozaki E, Suenaga M, Chin K, Yamaguchi K. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. *Cancer Chemother Pharmacol.* 2020 Feb;85(2):265-272.
5. Takahari D, Ito S, Mizusawa J, Katayama H, Terashima M, Sasako M, Morita S, Nomura T, Yamada M, Fujiwara Y, Kimura Y, Ikeda A, Kadokawa Y, Sano T; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). *Gastric Cancer.* 2020 Mar;23(2):293-299.
6. Takahari D, Chin K, Ishizuka N, Takashima A, Minashi K, Kadokawa S, Nishina T, Nakajima TE, Amagai K, Machida N, Goto M, Taku K, Wakatsuki T, Shoji H, Hironaka S, Boku N, Yamaguchi K. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. *Gastric Cancer.* 2019 Nov;22(6):1238-1246.
7. Osumi H, Takahari D, Chin K, Ogura M, Ichimura T, Wakatsuki T, Suzuki T, Ota Y, Nakayama I, Ooki A, Suenaga M, Shinozaki E, Yamaguchi K. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. *Oncotargets Ther.* 2018 Nov 23;11:8301-8307.

8. Fukuda N, Takahari D, Wakatsuki T, Osumi H, Nakayama I, Matsushima T, Ichimura T, Ogura M, Ozaka M, Suenaga M, Shinozaki E, Chin K, Yamaguchi K. Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel. *Oncotarget*. 2018 Mar 8;9(20):15219-15227.
9. Murahashi S, Takahari D, Wakatsuki T, Fukuda N, Ichimura T, Ogura M, Ozaka M, Shinozaki E, Nakayama I, Matsushima T, Osumi H, Chin K, Yamaguchi K. A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. *Int J Clin Oncol*. 2018 Feb;23(1):92-97.
10. Takahari D, Mizusawa J, Koizumi W, Hyodo I, Boku N. Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials. *Gastric Cancer*. 2017 Sep;20(5):757-763.
11. Takahari D. Second-line chemotherapy for patients with advanced gastric cancer. *Gastric Cancer*. 2017 May;20(3):395-406. Review.
12. Takahari D, Boku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, Yamazaki K, oizumi W, Fukase K, Yamaguchi K, Goto M, Nishina T, Tamura T, Tsuji A, Ohtsu A. Determination of Prognostic Factors in Japanese Patients With Advanced Gastric Cancer Using the Data From a Randomized Controlled Trial, Japan Clinical Oncology Group 9912. *Oncologist*. 2014 Apr;19(4):358-66.
13. Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, Konishi M, Yasui H, Terashima M, Goto M, Tanigawa N, Shirao K, Sano T, Sasako M. Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. *Gastric Cancer*. 2014 Apr;17(2):383-6.
14. Takahari D, Shimada Y, Takeshita S, Nishitani H, Takashima A, Okita N, Hirashima Y, Kato K, Hamaguchi T, Yamada Y, Shirao K. Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer. *Gastric Cancer*. 2010 Aug;13(3):186-90.
15. Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, Kinoshita T, Yasui H, Terashima M, Goto M, Tanigawa N, Shirao K, Sano T, Sasako M. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. *Cancer Chemother Pharmacol*. 2011 Jun;67(6):1423-8.
16. Takahari D, Yamada Y, Okita NT, Honda T, Hirashima Y, Matsubara J, Takashima A, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. *Oncology*. 2009;76(1):42-8.